Bracket announces the addition of J. Matthew Bond as Chief Financial Officer.

Bracket, a leading clinical trial specialty services provider, today announced the addition of J. Matthew Bond as Chief Financial Officer and as a member of the company’s leadership team.

Matt brings more than 25 years of experience to Bracket, primarily through leadership positions in growth oriented, pharmaceutical outsourcing firms. Most recently, Matt co-founded and served as the CFO of Aptiv Solutions, a mid-size, specialized contract research organization focused on adaptive methods for biopharmaceutical clinical development and in the medical device approval market. During his tenure, he grew the business from its startup phase to a large multi-national organization primarily through a series of strategic acquisitions, and was the recognized leader in the development and execution of adaptive clinical trials until its acquisition in 2014. Previously, Matt was Executive Vice President and CFO of a global, growth oriented CRO, where over 6 years he led a very successful initial public offering and created significant value for the various stakeholders.

“I couldn’t be more thrilled to welcome Matt to Bracket where he will undoubtedly make an immediate impact,” said Jeff Kinell, president and CEO of Bracket. “I am particularly impressed with Matt’s ability to lead a financial function in a complex, industry-leading business, while maintaining an unrelenting focus on serving and advocating for his company’s customers.”

“I can’t imagine a more exciting time to join Bracket,” Mr. Bond said. “Bracket is leading the transformation of eCOA, RTSM and Rater Training. Jeff and the leadership team recognize and appreciate that they’re making history, and I’m delighted to be a part of it.”

“Matt is extremely well qualified to serve as CFO,” said Dave Ament, Managing Partner, Boston office head, Parthenon Capital Partners and lead director of Bracket. “His deep leadership experience will be a strong complement to our leadership team and will be invaluable as we continue to drive our strategic and financial business transformation.”

About Bracket

Bracket, with seven offices and more than 500 employees worldwide, is a specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.

Bracket Presents New Research at CTAD 2015 on eCOA Solutions for Alzheimer’s Disease

Bracket, an industry leader in Rater Training and Quality Assurance services for Alzheimer’s Disease clinical trials, has presented new data demonstrating that the use of the Bracket Rater Station, a therapeutically designed eCOA solution, can significantly improve data quality by reducing ratings errors. The combination of electronic versions of the ADAS-Cog, MMSE, and CDR, with predictive analytics and related enhancements beyond their respective paper version, improved administration and scoring of the scales and minimized “rater drift” over the course of a trial.

“Bracket developed an eCOA solution from these scales based on years of clinical experience in both training and quality assurance programs in dozens of clinical trials. These findings reinforce our belief that issues of ratings variability and noisy data can be minimized through innovative methodologies and cutting-edge technology,” said Dr. David Miller, Bracket’s Therapeutic Area Leader for Alzheimer’s Disease.

“We have reported statistically significant reductions in error rates associated our eCOA product. As we continue to implement this proprietary solution in new trials, we can learn more about the opportunities to further improve quality,” continued Dr. Miller.

 

ecoa results

Issues surrounding clinical outcomes variability have always troubled researchers conducting clinical studies in Alzheimer’s disease. Bracket has been a constant innovator in addressing these problems, and is planning additional analysis of ongoing eCOA programs. Bracket eCOA tools have been developed by clinicians, and tested extensively with clinical researchers prior to implementation into clinical trials.

The research was presented at the 8th Clinical Trials On Alzheimer’s Disease meeting in Barcelona, Spain, in a poster titled “The Impact of Electronic Administration of the ADAS-Cog, MMSE and CDR-SB on Clinical Trial Data Quality.” A copy of the poster can be found here.

About Bracket

Bracket, with seven offices and more than 500 employees worldwide, is a Specialty Services provider dedicated to helping pharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic Clinical Outcomes Assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable Clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improves outcomes through customized training and quality assurance programs.

Bracket to Present New Research at CTAD 2015

Issues surrounding clinical outcomes variability have always troubled researchers conducting clinical studies in Alzheimer’s disease. Bracket has been a constant innovator in addressing these problems, and will present new research this week that reinforces earlier findings that Bracket’s clinical and technology interventions can improve data quality in AD clinical trials.

2015-CTAD-1_2__pdf__1_page_The research is being presented at the 8th Clinical Trials On Alzheimer’s Disease meeting. In a paper titled “The Impact of Electronic Administration of the ADAS-Cog, MMSE And CDR-SB On Clinical Trial Data Quality,” Dr. David Miller, Bracket’s Therapeutic Area Leader for Alzheimer’s Disease, will show that the use of Bracket’s proprietary Rater Station eCOA platform significantly reduced errors in the administration of the most important clinical outcomes in an Alzheimer’s disease study.

The CTAD 2015 meeting opens on Thursday 5 November in Barcelona.

Bracket Presentations at CTAD 2015:

The Impact of Electronic Administration of the ADAS-Cog, MMSE And CDR-SB On Clinical Trial Data Quality. Miller, Feaster, Hernandez, He, Kott. Poster P1-42.

A Methodology for Evaluating Clinical Trial Sites and Raters Based on Performance Data. Miller, Feaster, Allen, Gratkowski, Butler. Poster P1-14.